New Multifunctional Agents for Potential Alzheimer’s Disease Treatment Based on Tacrine Conjugates with 2-Arylhydrazinylidene-1,3-Diketones
作者:Natalia A. Elkina、Maria V. Grishchenko、Evgeny V. Shchegolkov、Galina F. Makhaeva、Nadezhda V. Kovaleva、Elena V. Rudakova、Natalia P. Boltneva、Sofya V. Lushchekina、Tatiana Y. Astakhova、Eugene V. Radchenko、Vladimir A. Palyulin、Ekaterina F. Zhilina、Anastasiya N. Perminova、Luka S. Lapshin、Yanina V. Burgart、Victor I. Saloutin、Rudy J. Richardson
DOI:10.3390/biom12111551
日期:——
development of new effective therapeutic agents for AD is one of the most urgent and challenging tasks. To address this need, we used an aminoalkylene linker to combine the well-known anticholinesterase drug tacrine with antioxidant 2-tolylhydrazinylidene-1,3-diketones to create 3 groups of hybrid compounds as new multifunctional agents with the potential for AD treatment. Lead compounds of the new conjugates
阿尔茨海默病 (AD) 被认为是一种现代流行病,因为它在全球范围内的患病率不断上升,并产生严重的医学社会后果,包括治疗和患者护理的经济负担。开发新的有效治疗AD的药物是最紧迫和最具挑战性的任务之一。为了满足这一需求,我们使用氨基亚烷基连接体将著名的抗胆碱酯酶药物他克林与抗氧化剂 2-甲苯基亚肼基-1,3-二酮结合起来,创建了 3 组杂合化合物,作为具有 AD 治疗潜力的新型多功能药物。新缀合物的先导化合物可有效抑制乙酰胆碱酯酶(AChE,IC 50 0.24–0.34 µM)和丁酰胆碱酯酶(BChE,IC 50 0.036–0.0745 µM),对脱靶羧酸酯酶的抑制较弱。抗AChE活性随着亚烷基间隔基的延长而增加,这与分子对接一致,这表明化合物与AChE的催化活性位点和外周阴离子位点(PAS)结合,这与混合型可逆抑制一致。 PAS 结合以及有效的丙啶置换表明该杂交体具有阻断 AChE 诱导的